ESGO Congress | Conference

Cisplatin Chemoradiation Proves Benefit in Stage IIIB Cervical Cancer

November 9th 2017

Umesh Mahantshetty, MD, shares his insight on the state of cervical cancer treatment in developing countries.

Final Results Confirm OS Benefit Associated with Olaparib in Relapsed Platinum-Sensitive Serous Ovarian Cancer

November 9th 2017

Maintenance therapy with olaparib monotherapy provides clinically significant, long-term treatment benefits and is safe in patients with platinum-sensitive relapsed serous ovarian cancer.

Dr. Sessa Discusses ATR Inhibitors in BRCA-Mutated Tumors

November 8th 2017

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses ataxia–telangiectasia and Rad3 related (ATR) inhibitors in patients with ovarian cancer who have BRCA-mutated tumors.

Dr. Haldorsen on the Role of Imaging in the Diagnosis of Endometrial Cancer

November 8th 2017

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the role of imaging in the diagnosis of endometrial cancer.

Dr. Ledermann on the Results of the ARIEL3 Trial in Ovarian Cancer

November 8th 2017

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the results of the ARIEL3 trial in ovarian cancer.

Dr. Bosch on the HPV Vaccination in the Prevention of Cervical Cancer

November 8th 2017

Xavier Bosch, MD, MPH, Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia–Catalan Institute of Oncology, introduces a second-generation vaccination against the human papilloma virus (HPV) for the prevention of cervical cancer.

Expert Discusses Rucaparib Maintenance in Ovarian Cancer

November 8th 2017

Jonathan Ledermann, MD, discussed these results, as well as the future of PARP inhibitors in the maintenance setting for patients with ovarian cancer.

Survey Shows Patients Consider Several Factors of Maintenance Therapy for Ovarian Cancer Treatment

November 8th 2017

Patients with ovarian cancer were unified in their responses regardless of age, disease stage, or whether they had primary or recurrent disease, and were more likely to opt to receive maintenance therapy if it could offer delay of disease progression and allow patients to maintain or improve their quality of life.

PALB2 Mutation Implicated in Higher Risk of Breast Cancer, Not Ovarian

November 8th 2017

Deleterious mutations in the PALB2 gene may account for the development of breast cancer in women with an elevated risk due to a family history of breast or ovarian cancer, but who test negative for the BRCA1 or BRCA2 genes.

Maintenance Rucaparib Extended PFS in Women with Platinum-Sensitive Recurrent Ovarian Cancer

November 8th 2017

Rucaparib delayed disease recurrence in the intent to treat population and across subgroups of women with ovarian cancer.

x